Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claes Held

Showing results (181-190 of 227) with videos related to

Pageof 23
Sort By:
The New England Journal of Medicine|April 8, 2024
FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial InfarctionFelix Böhm, Brynjölfur Mogensen, Thomas Engstrøm, et al.
Circulation|March 9, 2022
Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIADaniel B Mark, John A Spertus, Robert Bigelow, et al.
Journal of the American Heart Association|September 2, 2017
Self-Reported Health and Outcomes in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Emil Hagström, Claes Held, et al.
Lancet (London, England)|October 31, 2024
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trialDavid Erlinge, Jonas Andersson, Ole Fröbert, et al.
Neurology|March 1, 2019
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 studyJackie Bosch, Martin O'Donnell, Balakumar Swaminathan, et al.
The New England Journal of Medicine|September 3, 2019
Ticagrelor in Patients with Stable Coronary Disease and DiabetesP Gabriel Steg, Deepak L Bhatt, Tabassome Simon, et al.
European Journal of Heart Failure|September 16, 2024
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and designLars H Lund, Stefan James, Adam D DeVore, et al.
Lancet (London, England)|September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trialDeepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
Stroke|May 14, 2021
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 TrialJackie Bosch, Eva M Lonn, Gilles R Dagenais, et al.
Journal of the American Heart Association|June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart DiseaseLars Wallentin, Claes Held, Paul W Armstrong, et al.
Pageof 23

Showing results (181-190 of 227) with videos related to

Sort By:
Pageof 23
The New England Journal of Medicine|April 8, 2024
FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial InfarctionFelix Böhm, Brynjölfur Mogensen, Thomas Engstrøm, et al.
Circulation|March 9, 2022
Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIADaniel B Mark, John A Spertus, Robert Bigelow, et al.
Journal of the American Heart Association|September 2, 2017
Self-Reported Health and Outcomes in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Emil Hagström, Claes Held, et al.
Lancet (London, England)|October 31, 2024
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trialDavid Erlinge, Jonas Andersson, Ole Fröbert, et al.
Neurology|March 1, 2019
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 studyJackie Bosch, Martin O'Donnell, Balakumar Swaminathan, et al.
The New England Journal of Medicine|September 3, 2019
Ticagrelor in Patients with Stable Coronary Disease and DiabetesP Gabriel Steg, Deepak L Bhatt, Tabassome Simon, et al.
European Journal of Heart Failure|September 16, 2024
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and designLars H Lund, Stefan James, Adam D DeVore, et al.
Lancet (London, England)|September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trialDeepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
Stroke|May 14, 2021
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 TrialJackie Bosch, Eva M Lonn, Gilles R Dagenais, et al.
Journal of the American Heart Association|June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart DiseaseLars Wallentin, Claes Held, Paul W Armstrong, et al.
Pageof 23